Document Detail


Therapeutic drug monitoring of amikacin in preterm and term infants.
MedLine Citation:
PMID:  19495517     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
INTRODUCTION: Amikacin is a commonly-prescribed drug used for the empirical treatment of bacterial infections in neonates. A marked change in the pharmacokinetics of amikacin has been reported during neonatal life. Amikacin has a very narrow therapeutic range and can cause very serious side effects such as nephrotoxicity and ototoxicity. The current therapeutic dose of amikacin, i.e. 15 mg/kg of body weight, may increase the risk of toxicity in preterm infants with immature renal functions. We aimed to determine the frequency of amikacin toxicity in preterm as compared to term infants by measuring its serum trough levels following the administration of the current therapeutic dose. METHODS: A comparative study was conducted at the neonatal intensive care unit of the Military Hospital, Rawalpindi, Pakistan. A total of 104 infants (52 term and 52 preterm) receiving amikacin at a dose of 15 mg/kg of their body weight, once daily for bacterial infection, were included. After clinical evaluation, serum creatinine levels were measured at admission and on the third day. Amikacin trough levels were taken after 72 hours of therapy and measured on the TDx Abbot Drug Analyser. RESULTS: The gestational age range was 37-40 weeks in term and 29-36 weeks in preterm infants. The term and preterm infants had a median weight of 2.8 kg and 2.1 kg, respectively. The preterm infants had significantly higher median (range) 11.33 (1.50-42.60) ug/ml levels of serum amikacin as compared to 8.5 (2.8-33.0) ug/ml in term infants (p-value is less than 0.01). The preterm infants had a high frequency of toxic 32 (62 percent) and subtherapeutic 12 (23 percent) levels, as compared to 11 (21 percent) and 5 (10 percent) in term infants, respectively. Serum amikacin levels revealed a positive correlation with post-dose serum creatinine (r equals 0.48; p-value is less than 0.05). CONCLUSION: This study demonstrated that the current practice of amikacin treatment for bacterial infection needs to be adjusted due to unique pharmacokinetic variability in preterm infants. There is a need for regular therapeutic drug monitoring and renal function assessment in all infants receiving amikacin therapy in order to avoid nephrotoxicity.
Authors:
A Siddiqi; D A Khan; F A Khan; A Razzaq
Related Documents :
8362947 - Multicenter randomized, controlled trial of a preterm birth prevention program. collabo...
19301227 - Attitudes and practices regarding use of progesterone to prevent preterm births.
22436417 - Near-infrared spectroscopy: a report from the mcdonnell infant methodology consortium.
10688507 - Early pregnancy predictors of preterm birth: the role of a prolonged menstruation-conce...
7014297 - A controlled trial with inactivated poliovaccine.
8677027 - Unilateral cerebellar aplasia.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Singapore medical journal     Volume:  50     ISSN:  0037-5675     ISO Abbreviation:  Singapore Med J     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-06-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0404516     Medline TA:  Singapore Med J     Country:  Singapore    
Other Details:
Languages:  eng     Pagination:  486-9     Citation Subset:  IM    
Affiliation:
Department of Pathology, Army Medical College, National University of Sciences and Technology, Abid Majeed Road, Rawalpindi, Pakistan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Platelet count and neonatal sepsis: a high prevalence of Enterobacter spp.
Next Document:  CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia.